{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:17:41Z","timestamp":1789449461443,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"DOI":"10.1093\/eurheartj\/eht182","type":"journal-article","created":{"date-parts":[[2013,6,5]],"date-time":"2013-06-05T03:11:09Z","timestamp":1370401869000},"page":"2585-2591","source":"Crossref","is-referenced-by-count":170,"title":["The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease"],"prefix":"10.1093","volume":"34","author":[{"given":"Peter","family":"Nordstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Religa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Eriksdotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,6,4]]},"reference":[{"key":"key\n\t\t\t\t20170626082841_EHT182C1","article-title":"The 10 leading causes of death by broad income group","author":"WHO"},{"key":"key\n\t\t\t\t20170626082841_EHT182C2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082841_EHT182C3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082841_EHT182C4","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170626082841_EHT182C5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/01.CIR.0000105721.71640.DA","article-title":"Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats","volume":"109","author":"Li","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082841_EHT182C6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ana.20454","article-title":"Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production","volume":"57","author":"Pollak","year":"2005","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20170626082841_EHT182C7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.exger.2004.12.003","article-title":"Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients","volume":"40","author":"Reale","year":"2005","journal-title":"Exp Gerontol"},{"key":"key\n\t\t\t\t20170626082841_EHT182C8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jneuroim.2003.11.003","article-title":"Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines","volume":"148","author":"Reale","year":"2004","journal-title":"J Neuroimmunol"},{"key":"key\n\t\t\t\t20170626082841_EHT182C9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u2018Mini-mental state\u2019. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"key\n\t\t\t\t20170626082841_EHT182C10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000337038","article-title":"Dementia diagnosis differs in men and women and depends on age and dementia severity: data from SveDem, the Swedish Dementia Quality Registry","volume":"33","author":"Religa","year":"2012","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170626082841_EHT182C11","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/ije\/30.suppl_1.S30","article-title":"A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden","volume":"30","author":"Hammar","year":"2001","journal-title":"Int J Epidemiol"},{"key":"key\n\t\t\t\t20170626082841_EHT182C12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000102568","article-title":"Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials","volume":"24","author":"Winblad","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20170626082841_EHT182C13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170626082841_EHT182C14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer's disease - results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20170626082841_EHT182C15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1034\/j.1601-5215.2002.51024.x","article-title":"Getting donepezil into the nursing home","volume":"51","author":"Finucane","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t20170626082841_EHT182C16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20170626082841_EHT182C17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2389.2003.51260.x","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden","volume":"51","author":"Feldman","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t20170626082841_EHT182C18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000066669","article-title":"An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial","volume":"15","author":"Wimo","year":"2003","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key\n\t\t\t\t20170626082841_EHT182C19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/030079905X56565","article-title":"Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period","volume":"21","author":"Bullock","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20170626082841_EHT182C20","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626082841_EHT182C21","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170626082841_EHT182C22","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170626082841_EHT182C23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626082841_EHT182C24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archneur.58.3.417","article-title":"Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression","volume":"58","author":"Farlow","year":"2001","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20170626082841_EHT182C25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082841_EHT182C26","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1073\/pnas.0600506103","article-title":"Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia","volume":"103","author":"Pavlov","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20170626082841_EHT182C27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbi.2008.06.011","article-title":"Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway","volume":"23","author":"Pavlov","year":"2009","journal-title":"Brain Behav Immun"},{"key":"key\n\t\t\t\t20170626082841_EHT182C28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1365-2796.2009.02098.x","article-title":"Cholinergic control of inflammation","volume":"265","author":"Rosas-Ballina","year":"2009","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20170626082841_EHT182C29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2010.07.027","article-title":"Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice","volume":"213","author":"Inanaga","year":"2010","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170626082841_EHT182C30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12576-009-0071-5","article-title":"Effect of the cholinesterase inhibitor donepezil on cardiac remodeling and autonomic balance in rats with heart failure","volume":"60","author":"Okazaki","year":"2010","journal-title":"J Physiol Sci"},{"key":"key\n\t\t\t\t20170626082841_EHT182C31","doi-asserted-by":"crossref","first-page":"e1000157","DOI":"10.1371\/journal.pmed.1000157","article-title":"Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study","volume":"6","author":"Park-Wyllie","year":"2009","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170626082841_EHT182C32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1533317512442999","article-title":"Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?","volume":"27","author":"Isik","year":"2012","journal-title":"Am J Alzheimers Dis Other Demen"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/33\/2585\/17896137\/eht182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T22:43:15Z","timestamp":1503441795000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/eht182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,4]]},"references-count":32,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2013,6,4]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht182","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6,4]]}}}